2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118064
    (R)-Thionisoxetine 163059-33-4 98%
    (R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence.
    (R)-Thionisoxetine
  • HY-118072
    Aspalatone 147249-33-0 98%
    Aspalatone is an orally active antiplatelet aggregant with IC50 of 180 μM. Aspalatone has antioxidant and neuroprotective activities.
    Aspalatone
  • HY-118120
    GEMSA 77482-44-1 98%
    GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia.
    GEMSA
  • HY-118127
    Rilapine 79781-95-6 98%
    Rilapine is an atypical antipsychotic agent.
    Rilapine
  • HY-118182
    Tidembersat 175013-73-7 98%
    Tidembersat (Example 4) is a benzopyran derivative that can be used in the research of a variety of CNS disorders and traumatic brain injury.
    Tidembersat
  • HY-118222
    KBR 2822 126988-60-1 98%
    KBR 2822 is an inhibitor of neurological target esterase (NTE) and has an inhibitory effect on AChE. KBR 2822 can aggravate neurological damage under certain conditions, but does not cause neurological disease when used alone in the absence of direct neurotoxicity or biochemical damage.
    KBR 2822
  • HY-118238
    Remeglurant 1309783-00-3 98%
    Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC50 of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD).
    Remeglurant
  • HY-118256
    LSN2814617 1313498-17-7 98%
    LSN2814617 is an orally active, potent, brain-penetrant, and selective mGlu5 (metabotropic glutamate 5) positive allosteric modulator (PAM), with EC50 values of 52 nM (Human mGlu5) and 42 nM (rat mGlu5). LSN2814617 shows wake-promoting effect. LSN2814617 can be used for schizophrenia research.
    LSN2814617
  • HY-118259
    L-663581 122384-14-9 98%
    L-663581 (FG-8205) is an agonist of benzodiazepine receptor, acting as a partial agonist at GABA A receptor.
    L-663581
  • HY-118308
    AHN-683 143934-15-0 98%
    AHN-683 is a luciferin-derived ligand that targets the peripheral benzodiazepine receptor (BDR).
    AHN-683
  • HY-118347
    Aspartame acesulfame 106372-55-8 98%
    Aspartame acesulfame is a methyl ester of a dipeptide. Aspartame acesulfame can be used as a synthetic nonnutritive sweetener. Aspartame acesulfame is composed of phenylalanine (50%), aspartic acid (40%) and methanol (10%).
    Aspartame acesulfame
  • HY-118350
    FR 75513 127975-78-4 98%
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-118352
    LB-205 1113025-86-7 98%
    LB-205 is a pan-histone deacetylase inhibitor (HDACi). LB-205 can be used for the research of acute traumatic brain injury.
    LB-205
  • HY-118387
    AVE-0118 498577-53-0 98%
    AVE-0118 is a nonselective Kv1.5 blocker with an IC50 of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against IKs, IKATP, and L-type Ca+ channels.
    AVE-0118
  • HY-118402
    PD 119819 105277-43-8 98%
    PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis.
    PD 119819
  • HY-118406
    Ethybenztropine 524-83-4 98%
    Ethybenztropine (Ponalid) is a muscarinic receptor blocker. Ethybenztropine is an anticholinergic and antihistaminergic agent.
    Ethybenztropine
  • HY-118407
    LY56110 26766-37-0 98%
    LY56110 is an orally active aromatase inhibitor. LY56110 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 2.5 and 11 μΜ, respectively. LY56110 can be used for neurological disorder study.
    LY56110
  • HY-118414
    20-Ethyl prostaglandin E2 37492-24-3 98%
    20-Ethyl prostaglandin E2 (compound 62) is a PG analog that stimulates Nurr1-dependent transcriptional activity.
    20-Ethyl prostaglandin E2
  • HY-118424
    JNJ-55511118 2036081-86-2 98%
    JNJ-55511118 is a highly potent, reversible, and selective AMPA receptor inhibitor selective for TARP-γ8. JNJ-55511118 fully displaces the radioligand (20 nM) with the Ki of 26 nM in competition binding experiments. JNJ-55511118 is a tool molecule with potential therapeutic utility as an anticonvulsant or neuroprotectant.
    JNJ-55511118
  • HY-118450
    FR260010 free base 374555-75-6 98%
    FR260010 free base is a selective 5-HT2C receptor antagonist, with a Ki value of 1.1 nM.
    FR260010 free base
Cat. No. Product Name / Synonyms Application Reactivity